{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:55:16Z","timestamp":1790668516984,"version":"4.1.0"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"DOI":"10.1208\/s12248-026-01272-5","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T16:03:21Z","timestamp":1788451401000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Importance of Single Global Regulatory Standards for the Assessment of Generic and Biosimilar Medicines to Advance Patient Access"],"prefix":"10.1208","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7264-716X","authenticated-orcid":false,"given":"Antonela","family":"Rodriguez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1840-7320","authenticated-orcid":false,"given":"Vishalakshi","family":"Krishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5274-4314","authenticated-orcid":false,"given":"James E.","family":"Polli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8023-8080","authenticated-orcid":false,"given":"Anna","family":"Schwendeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"1272_CR1","unstructured":"International Generic and Biosimilar Medicines Association. A vision for the global generic and biosimilar medicines Industry [Internet]. International generic and biosimilar medicines association; 2021 May [cited 2025 May 20]. Available from: https:\/\/www.igbamedicines.org\/doc\/IGBA_Whitepaper_A%20Vision%20for%20the%20Global%20Generic%20and%20Biosimilar%20Medicines%20Industry_registered-user.pdf."},{"key":"1272_CR2","unstructured":"van den Heuvel R, Rollman MJ, Champagne S, Stoll J. Generics 2030: Three strategies to curb the downward spiral [Internet]. KPMG; 2020 [cited 2025 May 20]. Available from: https:\/\/kpmg.com\/kpmg-us\/content\/dam\/kpmg\/pdf\/2023\/generics-2030.pdf."},{"key":"1272_CR3","unstructured":"Aitken M, Pritchett J, Kleinrock M. Global use of medicines 2024: outlook to 2028 [Internet]. IQVIA; 2024 Jan [cited 2025 May 20]. Available from: https:\/\/www.iqvia.com\/-\/media\/iqvia\/pdfs\/institute-reports\/the-global-use-of-medicines-2024-outlook-to-2028\/iqvia-institute-global-use-of-medicines-2024-forweb.pdf."},{"key":"1272_CR4","unstructured":"Association for Accessible Medicines. The U.S. Generic & Biosimilar medicines savings report [Internet]. Association for accessible medicines; 2024 Sep [cited 2025 May 20]. Available from: https:\/\/accessiblemeds.org\/wp-content\/uploads\/2025\/01\/AAM-2024-Generic-Biosimilar-Medicines-Savings-Report.pdf."},{"key":"1272_CR5","unstructured":"Association for Accessible Medicines. The U.S. generic & biosimilar medicines savings report [Internet]. Association for accessible medicines; 2025 Sep. Located at: 10\/27\/2025. Available from: https:\/\/accessiblemeds.org\/wp-content\/uploads\/2025\/09\/AAM-2025-Generic-Biosimilar-Medicines-Savings-Report-WEB.pdf."},{"key":"1272_CR6","unstructured":"Troein P, Newton M, Travaglio M, Stoddart K. Beneath the surface: unravelling the true value of generic medicines [Internet]. 2024 Apr [cited 2025 May 20]. Available from: https:\/\/www.iqvia.com\/-\/media\/iqvia\/pdfs\/library\/white-papers\/iqvia-true-value-of-generic-medicines-04-24-forweb.pdf."},{"key":"1272_CR7","unstructured":"Aitken M, Kleinrock M. Global use of medicines 2023: Outlook to 2027 [Internet]. IQVIA; 2023 Jan [cited 2025 May 20]. Available from: https:\/\/www.iqvia.com\/-\/media\/iqvia\/pdfs\/institute-reports\/the-global-use-of-medicines-2023\/iqvia-institute-global-use-of-medicines-2023-report-01-23-forweb.pdf."},{"issue":"1","key":"1272_CR8","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12962-023-00441-z","volume":"21","author":"M Kosaka","year":"1961","unstructured":"Kosaka M, Ozaki A, Kaneda Y, Saito H, Yamashita E, Murayama A, et al. Generic drug crisis in Japan and changes leading to the collapse of universal health insurance established in 1961: the case of Kobayashi Kako Co. Ltd. Cost Effect Resource Allocation\u202f: C\/E. 1961;21(1):35. https:\/\/doi.org\/10.1186\/s12962-023-00441-z.","journal-title":"Cost Effect Resource Allocation : C\/E"},{"key":"1272_CR9","unstructured":"Conrad R, Lutter R. Generic competition and drug prices: new evidence linking greater generic competition and lower generic drug prices [Internet]. U.S. food & drug administration; 2019 Dec [cited 2025 May 20]. Available from: https:\/\/www.fda.gov\/media\/133509\/download."},{"key":"1272_CR10","unstructured":"Association for Accessible Medicines. The U.S. generic & biosimilar medicines savings report [Internet]. Association for accessible medicines; 2023 Sep [cited 2025 May 20]. Available from: https:\/\/accessiblemeds.org\/wp-content\/uploads\/2024\/11\/AAM-2023-Generic-Biosimilar-Medicines-Savings-Report-web.pdf."},{"key":"1272_CR11","unstructured":"U.S Food & Drug Administration. Abbreviated New Drug Application (ANDA) Forms and submission requirements [Internet]. U.S food & drug administration; 2025 Sep [cited 2025 Apr 20]. Available from: https:\/\/www.fda.gov\/drugs\/abbreviated-new-drug-application-anda\/abbreviated-new-drug-application-anda-forms-and-submission-requirements."},{"key":"1272_CR12","unstructured":"U.S Food & Drug Administration. Generic Drug User Fee Amendments (GDUFA) science and research priority initiatives for fiscal year (FY) 2025 [Internet]. U.S Food & Drug Administration; 2024 Nov [cited 2025 Sep 26]. Available from: https:\/\/www.fda.gov\/drugs\/generic-drugs\/fy-2025-gdufa-science-and-research-priorities."},{"key":"1272_CR13","unstructured":"U.S. Food & Drug Administration. Demonstrating equivalence of generic complex drug substances and formulations [Internet]. U.S. food & drug administration; 2017 Oct [cited 2025 Apr 20]. Available from: https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/demonstrating-equivalence-generic-complex-drug-substances-and-formulations."},{"key":"1272_CR14","unstructured":"U.S. Food & Drug Administration. Upcoming product-specific guidances for generic drug product development [Internet]. U.S. Food & Drug Administration; 2025 Jul [cited 2025 Sep 16]. Available from: https:\/\/www.fda.gov\/drugs\/guidances-drugs\/upcoming-product-specific-guidances-generic-drug-product-development#:~:text=This%20web%20page%20provides%20information,may%20be%20subject%20to%20change)."},{"key":"1272_CR15","unstructured":"Human Medicines Evaluation Division. QRD general principles regarding the SmPC information for a generic\/hybrid\/biosimilar product [Internet]. European Medicines Agency; 2018 Jun [cited 2025 May 20]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/quality-review-documents-general-principles-regarding-summary-product-characteristics-information-generic-hybrid-biosimilar-product_en.pdf."},{"key":"1272_CR16","unstructured":"Committee For Medicinal Products for Human Use. Guideline on the investigation of bioequivalence [Internet]. European Medicines Agency; 2010 Jan [cited 2025 May 20]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-investigation-bioequivalence-rev1_en.pdf."},{"key":"1272_CR17","unstructured":"European Union. Directive 2001\/83\/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use [Internet]. European Union; 2001 Nov [cited 2025 May 20]. Available from: https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/PDF\/?uri=CELEX:02001L0083-20210526."},{"key":"1272_CR18","unstructured":"Zhang L. FDA-EMA parallel scientific advice pilot program for complex generic\/hybrid drug products: SBIA webinar\u2014expanding generic drug access through international engagements [Internet]. U.S. Food & Drug Administration; 2024 Feb [cited 2025 May 20]. Available from: https:\/\/www.fda.gov\/media\/177934\/download."},{"key":"1272_CR19","unstructured":"Health Canada. Access to generic drugs in Canada [Internet]. Health Canada; 2024 May [cited 2025 May 20]. Available from: https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/drug-products\/fact-sheets\/access-to-generic-drugs.html."},{"key":"1272_CR20","unstructured":"Health Canada. Draft guidance document: generic drug equivalence: Medicinal ingredients [Internet]. Health Canada; 2019 Apr [cited 2025 May 20]. Available from: https:\/\/www.canada.ca\/content\/dam\/hc-sc\/documents\/services\/drugs-health-products\/public-involvement-consultations\/drug-products\/consultation-profile-draft-generic-drug-equivalence\/draft-generic-drug-equivalence-medicinal-ingredients-eng.pdf."},{"key":"1272_CR21","unstructured":"Health Canada. Guidance document: conduct and analysis of comparative bioavailability studies [Internet]. Health Canada; 2012 Feb [cited 2025 May 20]. Available from: https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/drug-products\/applications-submissions\/guidance-documents\/bioavailability-bioequivalence\/conduct-analysis-comparative.html."},{"key":"1272_CR22","unstructured":"Health Canada. Guidance document: use of a foreign\u2010sourced reference product as a Canadian reference product [Internet]. Health Canada; 2017 Nov [cited 2025 May 20]. Available from: https:\/\/www.canada.ca\/content\/dam\/hc-sc\/documents\/services\/drug-health-product-review-approval\/drug-products\/guidance-documents\/canadian-reference-product-guidance.pdf."},{"key":"1272_CR23","unstructured":"Health Canada. Notice: application of the definition of Canadian reference product [Internet]. Health Canada; 2024 Jan [cited 2025 May 20]. Available from: https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/drug-products\/announcements\/application-definition-canadian-reference-product.html."},{"key":"1272_CR24","unstructured":"Sano Y. Overview of generic drug policy and introduction of its review points\/BE guideline in Japan [Internet]. Pharmaceutical Safety and Environmental Health Bureau; 2017 Dec [cited 2025 May 20]. Available from: https:\/\/www.pmda.go.jp\/files\/000221883.pdf."},{"issue":"6","key":"1272_CR25","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1208\/s12248-024-00989-5","volume":"26","author":"R Kuribayashi","year":"2024","unstructured":"Kuribayashi R, Goto K, Ogawa T. Trend analysis of regulatory approvals for generics and biosimilars in Japan: 15 years of PMDA during fiscal years 2009\u20132023. AAPS J. 2024;26(6):113. https:\/\/doi.org\/10.1208\/s12248-024-00989-5.","journal-title":"AAPS J"},{"issue":"2","key":"1272_CR26","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s40262-020-00965-0","volume":"60","author":"R Kuribayashi","year":"2021","unstructured":"Kuribayashi R, Yamaguchi T, Takagi K. Modernization and strengthening of bioequivalence guidelines in Japan. Clin Pharmacokinet. 2021;60(2):145\u201351. https:\/\/doi.org\/10.1007\/s40262-020-00965-0.","journal-title":"Clin Pharmacokinet"},{"key":"1272_CR27","unstructured":"U.S Food & Drug Administration. Scientific considerations in demonstrating biosimilarity to a reference product [Internet]. U.S Food & Drug Administration; 2015 Apr [cited 2025 May 20]. Available from: https:\/\/www.fda.gov\/media\/82647\/download."},{"key":"1272_CR28","unstructured":"Committee for Medicinal Products for Human Use. Guideline on similar biological medicinal products [Internet]. European Medicines Agency; 2014 Oct [cited 2025 May 20]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-similar-biological-medicinal-products-rev1_en.pdf."},{"key":"1272_CR29","unstructured":"European Medicines Agency. European Medicines Agency to accept biosimilar reference medicines sourced outside European Economic Area [Internet]. European Medicines Agency; 2012 Sep [cited 2025 May 20]. Available from: https:\/\/www.ema.europa.eu\/en\/news\/european-medicines-agency-accept-biosimilar-reference-medicines-sourced-outside-european-economic-area#:~:text=*%20News.%20*%20European%20Medicines%20Agency%20to,reference%20medicines%20sourced%20outside%20European%20Eco."},{"key":"1272_CR30","unstructured":"European Medicines Agency. Multidisciplinary guidelines: biosimilar [Internet]. European Medicines Agency; 2006 Feb [cited 2026 Mar 6]. Available from: https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/research-development\/scientific-guidelines\/multidisciplinary-guidelines\/multidisciplinary-guidelines-biosimilar#tailored-clinical-approach-for-biosimilars-65348."},{"key":"1272_CR31","unstructured":"Health Canada. Guidance document: Information and submission requirements for biosimilar biologic drugs [Internet]. Health Canada; 2010 Mar [cited 2025 May 20]. Available from: https:\/\/www.canada.ca\/content\/dam\/hc-sc\/documents\/services\/drugs-health-products\/biologics-radiopharmaceuticals-genetic-therapies\/applications-submissions\/guidance-documents\/information-submission-requirements-biosimilar-biologic-drugs\/information-submission-requirements-biosimilar-biologic-drugs.pdf."},{"key":"1272_CR32","unstructured":"Pharmaceuticals and Medical Devices Agency. Guideline for ensuring quality, safety, and efficacy of biosimilars [Internet]. Pharmaceuticals and Medical Devices Agency; 2020 Feb [cited 2025 May 20]. Available from: https:\/\/www.pmda.go.jp\/files\/000267479.pdf."},{"issue":"4","key":"1272_CR33","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.47750\/pnr.2022.13.04.189","volume":"13","author":"K Chiluveri","year":"2022","unstructured":"Chiluveri K, Firos BB, John A, Menon G, Lobo EC, D\u2019Souza A, et al. Moving towards a single global approval of drugs: from concept to reality. Journal of Pharmaceutical Negative Results. 2022;13(4):1356\u201364. https:\/\/doi.org\/10.47750\/pnr.2022.13.04.189.","journal-title":"Journal of Pharmaceutical Negative Results"},{"issue":"2","key":"1272_CR34","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1080\/14740338.2024.2305709","volume":"23","author":"R Bhushan","year":"2024","unstructured":"Bhushan R, Martens J. Generic pharmaceuticals, regulatory aspects, bioequivalence investigation, and perception. Expert Opin Drug Saf. 2024;23(2):177\u201386. https:\/\/doi.org\/10.1080\/14740338.2024.2305709.","journal-title":"Expert Opin Drug Saf"},{"issue":"2","key":"1272_CR35","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s43441-024-00740-4","volume":"59","author":"TM Kirchlechner","year":"2025","unstructured":"Kirchlechner TM, Cohen HP. Global harmonization of biosimilar development by overcoming existing differences in regional regulatory requirements - outcomes of a descriptive review. Ther Innov Regul Sci. 2025;59(2):245\u201355. https:\/\/doi.org\/10.1007\/s43441-024-00740-4.","journal-title":"Ther Innov Regul Sci"},{"issue":"4","key":"1272_CR36","doi-asserted-by":"publisher","first-page":"306","DOI":"10.3390\/ph14040306","volume":"14","author":"B Ingram","year":"2021","unstructured":"Ingram B, Lumsden RS, Radosavljevic A, Kobryn C. Analysis of the regulatory science applied to a single portfolio of eight biosimilar product approvals by four key regulatory authorities. Pharmaceuticals (Basel). 2021;14(4):306. https:\/\/doi.org\/10.3390\/ph14040306.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"1","key":"1272_CR37","doi-asserted-by":"publisher","first-page":"2362450","DOI":"10.1080\/21645515.2024.2362450","volume":"20","author":"AS Jarab","year":"2024","unstructured":"Jarab AS, Abu H, Shrouq R, Al Meslamani AZ. Bridging the gap: The future of biosimilars regulations. Human Vaccines Immunotherapeutics. 2024;20(1):2362450. https:\/\/doi.org\/10.1080\/21645515.2024.2362450.","journal-title":"Human Vaccines Immunotherapeutics"},{"issue":"11","key":"1272_CR38","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1016\/j.drudis.2020.09.006","volume":"25","author":"MC Bielsky","year":"2020","unstructured":"Bielsky MC, Cook A, Wallington A, Exley A, Kauser S, Hay JL, et al. Streamlined approval of biosimilars: moving on from the confirmatory efficacy trial. Drug Discov Today. 2020;25(11):1910\u20138. https:\/\/doi.org\/10.1016\/j.drudis.2020.09.006.","journal-title":"Drug Discov Today"},{"issue":"5","key":"1272_CR39","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s40259-023-00619-0","volume":"37","author":"HP Cohen","year":"2023","unstructured":"Cohen HP, Turner M, McCabe D, Woollett GR. Future evolution of biosimilar development by application of current science and available evidence: the developer\u2019s perspective. BioDrugs. 2023;37(5):583\u201393. https:\/\/doi.org\/10.1007\/s40259-023-00619-0.","journal-title":"BioDrugs"},{"issue":"5","key":"1272_CR40","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1007\/s43441-020-00114-6","volume":"54","author":"S Lunawat","year":"2020","unstructured":"Lunawat S, Bhat K. Complex generic products: insight of current regulatory frameworks in US, EU and Canada and the need of harmonisation. Ther Innov Regul Sci. 2020;54(5):991\u20131000. https:\/\/doi.org\/10.1007\/s43441-020-00114-6.","journal-title":"Ther Innov Regul Sci"},{"issue":"3","key":"1272_CR41","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1177\/17411343231194755","volume":"19","author":"M Bhatt","year":"2023","unstructured":"Bhatt M, Tank S, Shah J, Maheshwari D. Regulatory framework and disparities of complex generics in United States, European Union & Latin America. J Generic Med. 2023;19(3):130\u201340. https:\/\/doi.org\/10.1177\/17411343231194755.","journal-title":"J Generic Med"},{"issue":"10","key":"1272_CR42","doi-asserted-by":"publisher","first-page":"001","DOI":"10.7324\/JAPS.2024.204337","volume":"14","author":"A Sreedevi","year":"2024","unstructured":"Sreedevi A, Musmade PB, Bhat K, Dharmagadda S, Janodia MD, Bhat BB, et al. A deep dive into the development of complex generics: a comprehensive review. J App Pharm Sci. 2024;14(10):001\u201314. https:\/\/doi.org\/10.7324\/JAPS.2024.204337.","journal-title":"J App Pharm Sci"},{"issue":"1","key":"1272_CR43","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1177\/17411343251313962","volume":"21","author":"R Shaikh","year":"2025","unstructured":"Shaikh R, Yadav K, Thummar K, Maheriya B, Chauhan S. Development of complex generics: insights into trends, challenges, and market opportunities. J Generic Med. 2025;21(1):4\u201316. https:\/\/doi.org\/10.1177\/17411343251313962.","journal-title":"J Generic Med"},{"issue":"336","key":"1272_CR44","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.jconrel.2021.06.017","volume":"10","author":"MN O\u2019Brien","year":"2021","unstructured":"O\u2019Brien MN, Jiang W, Wang Y, Loffredo DM. Challenges and opportunities in the development of complex generic long-acting injectable drug products. J Control Release. 2021;10(336):144\u201358. https:\/\/doi.org\/10.1016\/j.jconrel.2021.06.017.","journal-title":"J Control Release"},{"issue":"6","key":"1272_CR45","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s40259-023-00631-4","volume":"37","author":"N Kirsch-Stefan","year":"2023","unstructured":"Kirsch-Stefan N, Guillen E, Ekman N, Barry S, Knippel V, Killalea S, et al. Do the outcomes of clinical efficacy trials matter in regulatory decision-making for biosimilars? BioDrugs. 2023;37(6):855\u201371. https:\/\/doi.org\/10.1007\/s40259-023-00631-4.","journal-title":"BioDrugs"},{"issue":"3","key":"1272_CR46","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s40290-024-00525-y","volume":"38","author":"R Kuribayashi","year":"2024","unstructured":"Kuribayashi R, Hariu A, Nakano A, Kishioka Y. Survey of data package and sample size of comparative clinical studies for biosimilar developments from PMDA assessments. Pharm Med. 2024;38(3):225\u201339. https:\/\/doi.org\/10.1007\/s40290-024-00525-y.","journal-title":"Pharm Med"},{"issue":"2","key":"1272_CR47","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1057\/jphp.2013.53","volume":"35","author":"EFM \u2018t Hoen","year":"2014","unstructured":"\u2018t Hoen EFM, Hogerzeil HV, Quick JD, Sillo HB. A quiet revolution in global public health: The World Health Organization\u2019s Prequalification of Medicines Programme. J Public Health Policy. 2014;35(2):137\u201361. https:\/\/doi.org\/10.1057\/jphp.2013.53.","journal-title":"J Public Health Policy"},{"key":"1272_CR48","unstructured":"Committee for Medicinal Products for Human Use. Apixaban film-coated tablet 2.5 and 5 mg product-specific bioequivalence guidance [Internet]. European Medicines Agency; 2019 Jul [cited 2025 Aug 13]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/apixaban-film-coated-tablet-25-and-5-mg-product-specific-bioequivalence-guidance_en.pdf."},{"key":"1272_CR49","unstructured":"U.S Food & Drug Administration. Draft Guidance on Apixaban [Internet]. U.S Food & Drug Administration; 2024 Oct [cited 2025 Aug 13]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/psg\/PSG_202155.pdf."},{"key":"1272_CR50","unstructured":"U.S Food & Drug Administration. Draft Guidance on Liraglutide [Internet]. U.S Food & Drug Administration; 2024 Nov [cited 2025 Sep 10]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/psg\/PSG_022341.pdf."},{"issue":"6","key":"1272_CR51","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s13318-017-0409-y","volume":"42","author":"YL Wang","year":"2017","unstructured":"Wang YL, Hsu LF. Evaluating the feasibility of use of a foreign reference product for generic drug applications: a retrospective pilot study. Eur J Drug Metab Pharmacokinet. 2017;42(6):935\u201342. https:\/\/doi.org\/10.1007\/s13318-017-0409-y.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"11","key":"1272_CR52","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1007\/s40262-020-00912-z","volume":"59","author":"NA Charoo","year":"2020","unstructured":"Charoo NA. Converging generic drug product development: bioequivalence design and reference product selection. Clin Pharmacokinet. 2020;59(11):1335\u201355. https:\/\/doi.org\/10.1007\/s40262-020-00912-z.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"1272_CR53","doi-asserted-by":"publisher","first-page":"27","DOI":"10.18433\/J3X93K","volume":"21","author":"JE Van Oudtshoorn","year":"2018","unstructured":"Van Oudtshoorn JE, Garc\u00eda-Arieta A, Santos GML, Crane C, Rodrigues C, Simon C, et al. A survey of the regulatory requirements for BCS-Based biowaivers for solid oral dosage forms by participating regulators and organisations of the international generic drug regulators programme. J Pharm Pharm Sci. 2018;21(1):27\u201337. https:\/\/doi.org\/10.18433\/J3X93K.","journal-title":"J Pharm Pharm Sci"},{"issue":"3","key":"1272_CR54","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1208\/s12248-022-00691-4","volume":"24","author":"AM Abend","year":"2022","unstructured":"Abend AM, Zhang L, Fredro-Kumbaradzi E, Hoffelder T, Cohen MJ, Anand O, et al. Current approaches for dissolution similarity assessment, requirements, and global expectations. AAPS J. 2022;24(3):50. https:\/\/doi.org\/10.1208\/s12248-022-00691-4.","journal-title":"AAPS J"},{"issue":"7","key":"1272_CR55","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1016\/j.xphs.2023.04.016","volume":"112","author":"M Mehta","year":"2023","unstructured":"Mehta M, Polli JE, Seo P, Bhoopathy S, Berginc K, Kristan K, et al. Drug permeability - best practices for biopharmaceutics classification system (BCS)-based biowaivers: a workshop summary report. J Pharm Sci. 2023;112(7):1749\u201362. https:\/\/doi.org\/10.1016\/j.xphs.2023.04.016.","journal-title":"J Pharm Sci"},{"issue":"4","key":"1272_CR56","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s40259-019-00357-2","volume":"33","author":"CL Tu","year":"2019","unstructured":"Tu CL, Wang YL, Hu TM, Hsu LF. Analysis of pharmacokinetic and pharmacodynamic parameters in EU- versus US-licensed reference biological products: are in vivo bridging studies justified for biosimilar development? BioDrugs. 2019;33(4):437\u201346. https:\/\/doi.org\/10.1007\/s40259-019-00357-2.","journal-title":"BioDrugs"},{"issue":"1","key":"1272_CR57","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/cpt.2762","volume":"113","author":"T Arato","year":"2023","unstructured":"Arato T. Challenges for streamlining the development of biosimilars: a Japanese perspective. Clin Pharmacol Ther. 2023;113(1):30\u20136. https:\/\/doi.org\/10.1002\/cpt.2762.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"1272_CR58","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1002\/cpt.2785","volume":"113","author":"E Guillen","year":"2023","unstructured":"Guillen E, Ekman N, Barry S, Weise M, Wolff-Holz E. A data driven approach to support tailored clinical programs for biosimilar monoclonal antibodies. Clin Pharmacol Ther. 2023;113(1):108\u201323. https:\/\/doi.org\/10.1002\/cpt.2785.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"1272_CR59","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/jcph.6165","volume":"65","author":"P Ji","year":"2025","unstructured":"Ji P, Schrieber SJ, Glaser R, Chen J, Shukla C, Doddapaneni S, et al. A meta-analysis of the safety and immunogenicity of pharmacokinetic similarity studies and comparative clinical studies. J Clin Pharmacol. 2025;65(4):499\u2013507. https:\/\/doi.org\/10.1002\/jcph.6165.","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"1272_CR60","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s40259-025-00733-1","volume":"39","author":"M Schiestl","year":"2025","unstructured":"Schiestl M, Roy N, Trieb M, Park JP, Guillen E, Woollett G, et al. Analytical data and single-dose PK are sufficient to conclude comparable immunogenicity for biosimilars: an ustekinumab case study. BioDrugs. 2025;39(5):769\u201376. https:\/\/doi.org\/10.1007\/s40259-025-00733-1.","journal-title":"BioDrugs"},{"issue":"3","key":"1272_CR61","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s40259-020-00422-1","volume":"34","author":"M Schiestl","year":"2020","unstructured":"Schiestl M, Ranganna G, Watson K, Jung B, Roth K, Capsius B, et al. The path towards a tailored clinical biosimilar development. BioDrugs. 2020;34(3):297\u2013306. https:\/\/doi.org\/10.1007\/s40259-020-00422-1.","journal-title":"BioDrugs"},{"issue":"12","key":"1272_CR62","doi-asserted-by":"publisher","first-page":"e1860","DOI":"10.1016\/S2214-109X(22)00376-X","volume":"10","author":"K Jenei","year":"2022","unstructured":"Jenei K, Aziz Z, Booth C, Cappello B, Ceppi F, de Vries EGE, et al. Cancer medicines on the WHO model list of essential medicines: processes, challenges, and a way forward. Lancet Glob Health. 2022;10(12):e1860\u20136. https:\/\/doi.org\/10.1016\/S2214-109X(22)00376-X.","journal-title":"Lancet Glob Health"},{"issue":"1","key":"1272_CR63","doi-asserted-by":"publisher","first-page":"e145","DOI":"10.1016\/S2214-109X(22)00460-0","volume":"11","author":"S Morin","year":"2023","unstructured":"Morin S, Segafredo G, Piccolis M, Das A, Das M, Loffredi N, et al. Expanding access to biotherapeutics in low-income and middle-income countries through public health non-exclusive voluntary intellectual property licensing: considerations, requirements, and opportunities. Lancet Glob Health. 2023;11(1):e145\u201354. https:\/\/doi.org\/10.1016\/S2214-109X(22)00460-0.","journal-title":"Lancet Glob Health"},{"issue":"7","key":"1272_CR64","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/S1470-2045(25)00159-7","volume":"26","author":"Y Jiao","year":"2025","unstructured":"Jiao Y, Bai L, Wang J, Yan VKC, Chan EW, Na R, et al. Analysis of drug consumption and expenditure of WHO essential medicines for cancer in 40 countries and regions between 2012 and 2022: a multinational drug use study. Lancet Oncol. 2025;26(7):877\u201386. https:\/\/doi.org\/10.1016\/S1470-2045(25)00159-7.","journal-title":"Lancet Oncol"},{"issue":"1","key":"1272_CR65","doi-asserted-by":"publisher","first-page":"22","DOI":"10.2471\/BLT.23.289731","volume":"102","author":"E Costa","year":"2024","unstructured":"Costa E, Moja L, Wirtz VJ, van den Ham HA, Huttner B, Magrini N, et al. Uptake of orphan drugs in the WHO essential medicines lists. Bull World Health Organ. 2024;102(1):22\u201331. https:\/\/doi.org\/10.2471\/BLT.23.289731.","journal-title":"Bull World Health Organ"},{"issue":"2","key":"1272_CR66","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.sapharm.2025.10.008","volume":"22","author":"N Cornelissen","year":"2026","unstructured":"Cornelissen N, Zielhuis SW, van den Bemt PMLA, van den Bemt BJF. Causes and management of drug shortages: a scoping review. Res Social Adm Pharm. 2026;22(2):232\u201353. https:\/\/doi.org\/10.1016\/j.sapharm.2025.10.008.","journal-title":"Res Social Adm Pharm"},{"issue":"2","key":"1272_CR67","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1257\/jep.20241420","volume":"39","author":"RM Conti","year":"2025","unstructured":"Conti RM, Wosi\u0144ska ME. The economics of generic drug shortages: the limits of competition. J Econ Perspect. 2025;39(2):79\u2013102.","journal-title":"J Econ Perspect"},{"issue":"2","key":"1272_CR68","doi-asserted-by":"publisher","first-page":"192","DOI":"10.31662\/jmaj.2022-0179","volume":"6","author":"M Oura","year":"2023","unstructured":"Oura M, Saito H, Nishikawa Y. Shortage of nab-paclitaxel in Japan and around the World: issues in global information sharing. JMA J. 2023;6(2):192\u20135. https:\/\/doi.org\/10.31662\/jmaj.2022-0179.","journal-title":"JMA J"},{"issue":"1","key":"1272_CR69","doi-asserted-by":"publisher","first-page":"E2210299X269535","DOI":"10.2174\/012210299X269535231203164108","volume":"2","author":"S Patil","year":"2024","unstructured":"Patil S, Kumar S, Rao DM, Rewatkar K. Current regulatory framework and challenges for the approval of complex generics in the US and the EU. Current Indian Sci. 2024;2(1):E2210299X269535. https:\/\/doi.org\/10.2174\/012210299X269535231203164108.","journal-title":"Current Indian Sci"},{"issue":"3","key":"1272_CR70","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1377\/hlthaff.2022.00873","volume":"42","author":"S Reddy","year":"2023","unstructured":"Reddy S, Beall RF, Tu SS, Kesselheim AS, Feldman WB. Patent challenges and litigation on inhalers for asthma And COPD. Health Aff (Millwood). 2023;42(3):398\u2013406. https:\/\/doi.org\/10.1377\/hlthaff.2022.00873.","journal-title":"Health Aff (Millwood)"},{"issue":"8","key":"1272_CR71","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1080\/14712598.2023.2247972","volume":"23","author":"M Calamia","year":"2023","unstructured":"Calamia M, Abraham I. The economics of biosimilars and challenges to biosimilar adoption in low- and middle-income countries. Expert Opin Biol Ther. 2023;23(8):653\u20137. https:\/\/doi.org\/10.1080\/14712598.2023.2247972.","journal-title":"Expert Opin Biol Ther"},{"issue":"10","key":"1272_CR72","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1377\/hlthaff.2024.01476","volume":"44","author":"J Kao","year":"2025","unstructured":"Kao J, Van de Wiele VL, Beall RF, Sarpatwari A. Impact of risk evaluation and mitigation strategies on generic approvals Of US pharmaceutical products. Health Aff. 2025;44(10):1285\u201390. https:\/\/doi.org\/10.1377\/hlthaff.2024.01476.","journal-title":"Health Aff"},{"issue":"4","key":"1272_CR73","doi-asserted-by":"publisher","first-page":"558","DOI":"10.3390\/healthcare11040558","volume":"11","author":"H Althobaiti","year":"2023","unstructured":"Althobaiti H, Seoane-Vazquez E, Brown LM, Fleming ML, Rodriguez-Monguio R. Disentangling the cost of orphan drugs marketed in the United States. Healthcare (Basel). 2023;11(4):558. https:\/\/doi.org\/10.3390\/healthcare11040558.","journal-title":"Healthcare (Basel)"},{"key":"1272_CR74","unstructured":"International Council for Harmonisation. ICH Reflection Paper: Further Opportunities for Harmonization of Standards for Generic Drugs1 [Internet]. International Council for Harmonisation; 2018 Nov [cited 2025 May 20]. Available from: https:\/\/admin.ich.org\/sites\/default\/files\/2019-04\/ICH_ReflectionPaper_GenericDrugs_Final_2019_0130.pdf."},{"key":"1272_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2024.106741","volume":"196","author":"H Blume","year":"2024","unstructured":"Blume H, Wedemeyer S, Seidlitz A, Beuerle G, Klein S, Bilensoy E. Open forum conference on the ICH M13A bioequivalence guideline. Eur J Pharm Sci. 2024;196:106741. https:\/\/doi.org\/10.1016\/j.ejps.2024.106741.","journal-title":"Eur J Pharm Sci"},{"issue":"12","key":"1272_CR76","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.1111\/cts.13670","volume":"16","author":"J Kotsybar","year":"2023","unstructured":"Kotsybar J, Hakeem S, Zhang L, Jiang W. Global harmonization of immediate-release solid oral drug product bioequivalence recommendations and the impact on generic drug development. Clin Transl Sci. 2023;16(12):2756\u201364. https:\/\/doi.org\/10.1111\/cts.13670.","journal-title":"Clin Transl Sci"},{"key":"1272_CR77","unstructured":"International Council for Harmonisation. ICH harmonised guideline: Bioequivalence for immediaterelease solid oral dosage forms additional strengths biowaiver M13B [Internet]. International Council for Harmonisation; 2025 Mar [cited 2025 May 20]. Available from: https:\/\/database.ich.org\/sites\/default\/files\/M13B_Draft%20Guideline_Step2_2025_0212_0.pdf."},{"issue":"1","key":"1272_CR78","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-025-01159-x","volume":"28","author":"S Lee","year":"2025","unstructured":"Lee S, Baek J, Kang W, Kim E. Regulatory divergence in narrow therapeutic index drugs: a comparative review of the US, EU, Japan, Canada, and South Korea. AAPS J. 2025;28(1):19. https:\/\/doi.org\/10.1208\/s12248-025-01159-x.","journal-title":"AAPS J"},{"issue":"1","key":"1272_CR79","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-025-01020-1","volume":"27","author":"K Anim Anno","year":"2025","unstructured":"Anim Anno K, Mina M, Zhang Z, Zhang L, Jiang W. Analysis on the impact of U.S. FDA\u2019s narrow therapeutic index bioequivalence criteria on generic drug applications. AAPS J. 2025;27(1):42. https:\/\/doi.org\/10.1208\/s12248-025-01020-1.","journal-title":"AAPS J"},{"issue":"4","key":"1272_CR80","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1007\/s12325-022-02352-6","volume":"40","author":"CW Bertoncini","year":"2023","unstructured":"Bertoncini CW, Palacios MJC, Fritz MC, Rodriguez MP, Acevedo C, Hunzicker GA, et al. Levothyroxine bioequivalence study and its narrow therapeutic index: comparative bioavailability results between two formulations available in Latin America. Adv Ther. 2023;40(4):1644\u201354. https:\/\/doi.org\/10.1007\/s12325-022-02352-6.","journal-title":"Adv Ther"},{"issue":"5","key":"1272_CR81","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1159\/000493123","volume":"7","author":"E Fliers","year":"2018","unstructured":"Fliers E, Demeneix B, Bhaseen A, Brix TH. European Thyroid Association (ETA) and Thyroid Federation International (TFI) Joint Position Statement on the Interchangeability of Levothyroxine Products in EU Countries. Eur Thyroid J. 2018;7(5):238\u201342. https:\/\/doi.org\/10.1159\/000493123.","journal-title":"Eur Thyroid J"},{"key":"1272_CR82","unstructured":"International Council for Harmonisation. M13: Bioequivalence for immediate-release solid oral dosage forms [Internet]. International Council for Harmonisation; 2020 Jul [cited 2025 May 20]. Available from: https:\/\/database.ich.org\/sites\/default\/files\/ICH_M13_Concept_Paper_2020_0710_1.pdf."},{"key":"1272_CR83","doi-asserted-by":"publisher","first-page":"113","DOI":"10.18433\/jpps31491","volume":"24","author":"A Garcia Arieta","year":"2021","unstructured":"Garcia Arieta A, Simon C, Tam A, Mendes Lima Santos G, FreitasFernandes EA, Rodr\u00edguez Mart\u00ednez Z, et al. A survey of the regulatory requirements for the waiver of in vivo bioequivalence studies of generic products in certain dosage forms by participating regulators and organisations of the international pharmaceutical regulators programme. J Pharm Pharm Sci. 2021;24:113\u201326. https:\/\/doi.org\/10.18433\/jpps31491.","journal-title":"J Pharm Pharm Sci."},{"issue":"1","key":"1272_CR84","doi-asserted-by":"publisher","first-page":"28","DOI":"10.18433\/jpps30215","volume":"22","author":"A Garcia Arieta","year":"2019","unstructured":"Garcia Arieta A, Simon C, Lima Santos GM, Calder\u00f3nLojero IO, Rodr\u00edguez Mart\u00ednez Z, Rodrigues C, et al. A survey of the regulatory requirements for the acceptance of foreign comparator products by participating regulators and organizations of the international generic drug regulators programme. J Pharm Pharm Sci. 2019;22(1):28\u201336. https:\/\/doi.org\/10.18433\/jpps30215.","journal-title":"J Pharm Pharm Sci"},{"key":"1272_CR85","unstructured":"IPRP Biosimilars Working Group. Workshop Summary Report: Increasing the Efficiency of Biosimilar Development Programs \u2014 Reevaluating the Need for Comparative Clinical Efficacy Studies [Internet]. International Pharmaceutical Regulators Programme; 2024 May [cited 2025 May 20]. Available from: https:\/\/admin.iprp.global\/sites\/default\/files\/2024-07\/IPRP_BWG_Final%20IPRP%20Scientific%20Workshop%20Summary%20Report_2024_0506.pdf."},{"key":"1272_CR86","unstructured":"European Medicines Agency. Pilot programme for international cooperation in GMP inspection of manufacturers of sterile medicinal products for human use [Internet]. European Medicines Agency; 2019 Dec [cited 2025 Oct 3]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/other\/pilot-programme-international-cooperation-gmp-inspection-manufacturers-sterile-medicinal-products-human-use-terms-reference-participating-authorities_en.pdf."},{"key":"1272_CR87","unstructured":"Eglovitch J. FDA revises more than 800 PSGs in line with ICH M13A [Internet]. 2024 Nov [cited 2025 Oct 3]. Available from: https:\/\/www.raps.org\/News-and-Articles\/News-Articles\/2024\/11\/FDA-revises-more-than-800-PSGs-in-line-with-ICH-M1."},{"key":"1272_CR88","unstructured":"U.S. Food & Drug Administration. Upcoming Product-Specific Guidances for Generic Drug Product Development [Internet]. 2025 Nov [cited 2025 Dec 5]. Available from: https:\/\/www.fda.gov\/drugs\/guidances-drugs\/upcoming-product-specific-guidances-generic-drug-product-development."},{"key":"1272_CR89","unstructured":"U.S Food & Drug Administration. Development of Therapeutic Protein Biosimilars: Comparative Analytical Assessment and Other Quality-Related Considerations Guidance for Industry [Internet]. U.S. Food & Drug Administration; 2025 Sep [cited 2026 Mar 10]. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/development-therapeutic-protein-biosimilars-comparative-analytical-assessment-and-other-quality."},{"key":"1272_CR90","unstructured":"U.S. Food & Drug Administration. Scientific Considerations in Demonstrating Biosimilarity to a Reference Product: Updated Recommendations for Assessing the Need for Comparative Efficacy Studies Guidance for Industry [Internet]. U.S. Food & Drug Administration; 2025 Oct [cited 2025 Oct 29]. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/scientific-considerations-demonstrating-biosimilarity-reference-product-updated-recommendations."},{"key":"1272_CR91","unstructured":"U.S Food & Drug Administration. FDA Takes Further Steps to Streamline Biosimilar Development and Make Medicines More Affordable [Internet]. U.S Food & Drug Administration; 2026 Mar [cited 2026 Mar 18]. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-takes-further-steps-streamline-biosimilar-development-and-make-medicines-more-affordable."},{"issue":"5","key":"1272_CR92","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1002\/psp4.12968","volume":"12","author":"P Jayachandran","year":"2023","unstructured":"Jayachandran P. Advances in quantitative methods and modeling for complex generic drugs and opportunities to hybridize learnings between innovator and generic drug developers. CPT Pharmacometrics Syst Pharmacol. 2023;12(5):549\u201351. https:\/\/doi.org\/10.1002\/psp4.12968.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"1272_CR93","unstructured":"Zhao L. Quantitative Methods and Modeling to Support GDUFA Regulatory Science Research Program [Internet]. U.S Food & Drug Administration; 2017 May [cited 2025 Sep 19]. Available from: https:\/\/www.fda.gov\/files\/drugs\/published\/Quantitative-Methods-and-Modeling-to-Support-GDUFA-Regulatory-Science-Research-Program--Liang-Zhao--FDA.pdf."},{"issue":"4","key":"1272_CR94","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-025-03087-7","volume":"26","author":"R Ranjan","year":"2025","unstructured":"Ranjan R. Development of complex generics and similar biological products: an industrial perspective of reverse engineering. AAPS PharmSciTech. 2025;26(4):95. https:\/\/doi.org\/10.1208\/s12249-025-03087-7.","journal-title":"AAPS PharmSciTech"},{"issue":"2","key":"1272_CR95","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s11095-022-03319-6","volume":"40","author":"D Wu","year":"2023","unstructured":"Wu D, Sanghavi M, Kollipara S, Ahmed T, Saini AK, Heimbach T. Physiologically based pharmacokinetics modeling in biopharmaceutics: case studies for establishing the bioequivalence safe space for innovator and generic drugs. Pharm Res. 2023;40(2):337\u201357. https:\/\/doi.org\/10.1007\/s11095-022-03319-6.","journal-title":"Pharm Res"},{"key":"1272_CR96","unstructured":"U.S. Food & Drug Administration. Global Generic Drug Affairs [Internet]. 2025 Dec [cited 2025 Dec 5]. Available from: https:\/\/www.fda.gov\/drugs\/generic-drugs\/global-generic-drug-affairs."},{"issue":"2","key":"1272_CR97","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s43441-024-00740-4","volume":"59","author":"TM Kirchlechner","year":"2025","unstructured":"Kirchlechner TM, Cohen HP. Global harmonization of biosimilar development by overcoming existing differences in regional regulatory requirements - outcomes of a descriptive review. Ther Innov Regul Sci. 2025;59(2):245\u201355. https:\/\/doi.org\/10.1007\/s43441-024-00740-4.","journal-title":"Ther Innov Regul Sci"},{"issue":"4","key":"1272_CR98","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s40259-017-0227-4","volume":"31","author":"CJ Webster","year":"2017","unstructured":"Webster CJ, Woollett GR. A \u201cGlobal Reference\u201d comparator for biosimilar development. BioDrugs. 2017;31(4):279\u201386. https:\/\/doi.org\/10.1007\/s40259-017-0227-4.","journal-title":"BioDrugs"}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-026-01272-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-026-01272-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-026-01272-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:02:50Z","timestamp":1790665370000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12248-026-01272-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":98,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["1272"],"URL":"https:\/\/doi.org\/10.1208\/s12248-026-01272-5","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"assertion":[{"value":"29 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AI technology was utilized to correct grammatical errors throughout the manuscript.","order":1,"name":"Ethics","label":"A.I. Disclosure Statement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A.S. and V.K. declare financial interests for board membership, as a paid consultant, for research funding, and\/or as equity holder in EVOQ Therapeutics and ASKO Pharma. The University of Michigan has a financial interest in EVOQ Therapeutics, Inc. The remaining authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"128"}}